 |
The 130th Annual Meeting of APHA |
|
The 130th Annual Meeting of APHA |
3045.1: Monday, November 11, 2002: 8:30 AM-10:00 AM | |||
Panel Discussion | |||
| |||
| Drug research and development for developing country diseases has come to a virtual standstill in the last decades. Of the 1393 new drugs approved between 1975 and 1999, only 16 (or just over 1%) were specifically developed for tropical diseases and tuberculosis, diseases which account for 11.4% of the global disease burden. Innovative international efforts to revive pharmaceutical R&D for neglected diseases have been initiated in recent years, in particular through public-private partnerships focused on Malaria, Tuberculosis and HIV/AIDS. Other neglected diseases that are seriously disabling or life-threatening diseases and mainly affect people in developing countries, such as trypanosomiasis, remain characterized by inadequate or inexistent treatment options. The session with explore whether and how private-partnerships and other mechanisms can jumpstart the stalled R&D process for these neglected diseases. Panelists will present the experience and challenges of two new organizations, the Global Alliance for TB Drug Development and Medicines for Malaria Venture and discuss the Medecins Sans Frontieres Drugs for Neglected Diseases Initiative. Participants will discuss the ethical, economic, scientific, and public-health components of the health and drug research agenda and reflect on the priorities and strategies to address neglected diseases. | |||
| Learning Objectives: | |||
| Els Torrreele, MD, PhD Chris Hentschel, MD Joelle Tanguy | |||
| Joelle Tanguy | |||
| Organized by: | International Health | ||
| CE Credits: | CME, Nursing, Pharmacy, Social Work | ||